First Western Capital Management’s Regeneron Pharmaceuticals REGN Stock Holding History

First Western Capital Management’s Portfolio REGN Stock Details REGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q1	–	Sell	-950	Closed	-$349K	–	86
2016 Q4	$349K	Sell	950 -2,260	-70%	-$859K	0.19%	83
2016 Q3	$1.29M	Sell	3,210 -1,600	-33%	-$642K	0.5%	74
2016 Q2	$1.68M	Buy	4,810 +2,145	+80%	+$826K	0.61%	66
2016 Q1	$961K	Sell	2,665 -3,048	-53%	-$1.26M	0.34%	78
2015 Q4	$3.1M	Sell	5,713 -169	-3%	-$91.6K	0.97%	45
2015 Q3	$2.74M	Buy	5,882 +1,177	+25%	+$632K	0.91%	53
2015 Q2	$2.4M	Sell	4,705 -1,000	-18%	-$488K	0.77%	58
2015 Q1	$2.58M	Buy	+5,705	New	+$2.42M	0.77%	57
2014 Q3	–	Sell	-2,190	Closed	-$619K	–	144
2014 Q2	$619K	Sell	2,190 -3,775	-63%	-$1.12M	0.2%	105
2014 Q1	$1.79M	Buy	5,965 +570	+11%	+$176K	0.63%	57
2013 Q4	$1.49M	Buy	+5,395	New	+$1.55M	0.51%	73

Other funds holding REGN

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Sands Capital Management Arlington, Virginia $26.9B AUM 34.44% 1-Year Est. Return

Artisan Partners Milwaukee, Wisconsin $63.1B AUM 35.51% 1-Year Est. Return

Loomis, Sayles & Company Boston, Massachusetts $79.8B AUM 16.05% 1-Year Est. Return

Polen Capital Management Boca Raton, Florida $11.6B AUM 8.03% 1-Year Est. Return

First Western Capital Management's REGN Position: Q1 2017 in Review

First Western Capital Management sold out of Regeneron Pharmaceuticals (REGN) in Q1 2017, closing a stake of 950 shares — an estimated $349K sold.

First Western Capital Management first reported a position in REGN in Q4 2013 and held it in 11 quarters. The position peaked at $3.1M in Q4 2015. 579 funds tracked by Wall St. Rank hold REGN as of Q1 2017.

First Western Capital Management reported no remaining Regeneron Pharmaceuticals position as of Q1 2017 after selling out during the quarter.
First Western Capital Management sold 950 Regeneron Pharmaceuticals shares in Q1 2017, an estimated $349K.
First Western Capital Management first reported a position in Regeneron Pharmaceuticals in Q4 2013 and held it in 11 quarters.
First Western Capital Management's Regeneron Pharmaceuticals position peaked at $3.1M in Q4 2015.
579 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q1 2017.

Based on First Western Capital Management's 13F filing for Q1 2017, filed 26 Apr 2017.